Table of contents
January 2023 - Volume 108 - 1
Highlights from this issue
Global child health
- Hepatitis B virus and other transfusion-transmissible infections in child blood recipients in Lao People’s Democratic Republic: a hospital-based study (7 November, 2022)
In areas with high rates of anemia and thalassemia, children may receive numerous blood transfusions, placing them at risk of infections such as hepatitis B. Here, Lao children were evaluated for the risk of transfusion-associated hepatitis B infection.
- Social communication skill attainment in babies born during the COVID-19 pandemic: a birth cohort study (11 October, 2022)
This study compares children pre-Covid with a cohort born during a lockdown period and finds that the latter group have less advanced social communication skills than the former. The reason may be due to limited exposure to social communication experience.
- Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials (28 September, 2022)
This study looked at the use of prospective consent for participation in a study using the newborn screening blood spot to evaluate a genetic risk score for Type 1 Diabetes. This score was used to identify individuals who were offered an opportunity to participate in an interventional trial. The methodology provides a model for future clinically relevant population based genetic research.
- Assessing maternal alcohol consumption in pregnancy: does phosphatidylethanol measured from day 5 newborn blood spot cards have any value? An observational, population-based study (26 October, 2022)
This analysis of 500 blood spots demonstrates that phosphatidylethanol is not a useful biomarker for in-utero alcohol exposure.
- Pharmacokinetics and tolerability of intranasal or intravenous administration of nalbuphine in infants (13 September, 2022)
Swiss study to measure the pharmacokinetics of nalbuphine in babies when given intravenously and (more importantly) intranasally - generating important evidence supporting less invasive methods of administration.
- Use of xylometazoline in hospitalised infants: is it safe? A retrospective cohort study (28 September, 2022)
Xylometazoline spray or drops were evaluated for safety when used for nasal decongestion in infants less than 2 years of age in a Dutch study - and the study concludes they appear to be safe.